Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 12/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927162 | 1.00 | CXCR3 (0.44) | CXCR3TP53GAALMNAPKM | |
| SCHEMBL30376930 | 1.00 | CXCR3 (0.44) | CXCR3TP53GAALMNAPKM | |
| SCHEMBL19927159 | 1.00 | CXCR3 (0.44) | CXCR3TP53GAALMNAPKM | |
| SCHEMBL19931754 | 0.94 | CXCR3 (0.45) | CXCR3TP53GAAFNTAFNTB | |
| SCHEMBL19931746 | 0.93 | CXCR3 (0.45) | CXCR3TP53GAAFNTAFNTB | |
| SCHEMBL19927211 | 0.92 | CXCR3 (0.44) | CXCR3TP53GAAFNTAFNTB | |
| SCHEMBL19927221 | 0.92 | CXCR3 (0.44) | CXCR3TP53LMNAPKMFNTA | |
| SCHEMBL19927209 | 0.92 | CXCR3 (0.44) | CXCR3TP53GAAFNTAFNTB | |
| SCHEMBL26440006 | 0.92 | CXCR3 (0.44) | CXCR3TP53GAAFNTAFNTB | |
| SCHEMBL19931971 | 0.92 | CXCR3 (0.45) | CXCR3TP53FNTAFNTBHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CXCR3 1/4885TP53 1874/4885GAA 4863/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | CXCR3 1/4885TP53 1874/4885GAA 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.